| Literature DB >> 20812264 |
E C Cheon1, W Small, M J Strouch, S B Krantz, A Rademaker, M F Mulcahy, A B Benson, D J Bentrem, M S Talamonti.
Abstract
Bevacizumab (Avastin™; rhuMab VEGF), a monoclonal antibody targeting vascular endothelial growth factor (VEGF), has seen increased use in the perioperative treatment of colorectal and pancreatic cancer. Little is known, however, regarding its impact on surgical outcomes in patients undergoing resection. The objective of this review was to examine if the addition of bevacizumab to existing neoadjuvant regimens increases morbidity after cancer resection. J. Surg. Oncol. 2010;102:539-542.Entities:
Mesh：
Substances：
Year: 2010 PMID： 20812264 DOI： 10.1002/jso.21598
Source DB: PubMed Journal: J Surg Oncol ISSN： 0022-4790 Impact factor: 3.454